Neurizon Therapeutics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 52

Employees

  • Stock Symbol
  • NUZ

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.11
  • (As of Thursday Closing)

Neurizon Therapeutics General Information

Description

Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Contact Information

Website
www.neurizon.com
Formerly Known As
Pharmaust
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 4
  • 96-100 Albert Road
  • South Melbourne, Victoria 3205
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Stock Exchange
ASX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Level 4
  • 96-100 Albert Road
  • South Melbourne, Victoria 3205
  • Australia
+61 (03)

Neurizon Therapeutics Timeline

2022202320242025
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurizon Therapeutics Stock Performance

As of 19-Jun-2025, Neurizon Therapeutics’s stock price is $0.11. Its current market cap is $54.5M with 492M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.11 $0.10 $0.06 - $0.16 $54.5M 492M 328K

Neurizon Therapeutics Financials Summary

As of 31-Mar-2025, Neurizon Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 31,409 53,848 16,154 14,552
Revenue 1,898 2,450
EBITDA (5,847) (3,956) (946)
Net Income (5,029) (4,176) (1,238)
Total Assets 7,436 4,058 6,933
Total Debt 0 694 953
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neurizon Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neurizon Therapeutics‘s full profile, request access.

Request a free trial

Neurizon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the
Drug Discovery
South Melbourne, Australia
52 As of 2005

Basel, Switzerland
 

Plymouth, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurizon Therapeutics Competitors (7)

One of Neurizon Therapeutics’s 7 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Zynerba Pharmaceuticals Formerly VC-backed Plymouth, PA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Genelux Formerly VC-backed Westlake Village, CA
Dynavax Technologies Formerly VC-backed Emeryville, CA
You’re viewing 5 of 7 competitors. Get the full list »

Neurizon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurizon Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Neurizon Therapeutics‘s full profile, request access.

Request a free trial

Neurizon Therapeutics Acquisitions (2)

Neurizon Therapeutics’s most recent deal was a Merger/Acquisition with Pitney Pharmaceuticals for . The deal was made on 13-Aug-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pitney Pharmaceuticals 13-Aug-2013 Merger/Acquisition Other Healthcare Technology Systems
Pela Resources 10-Sep-2012 Merger/Acquisition Precious Metals and Minerals Mining
To view Neurizon Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Neurizon Therapeutics FAQs

  • When was Neurizon Therapeutics founded?

    Neurizon Therapeutics was founded in 2000.

  • Where is Neurizon Therapeutics headquartered?

    Neurizon Therapeutics is headquartered in South Melbourne, Australia.

  • What is the size of Neurizon Therapeutics?

    Neurizon Therapeutics has 52 total employees.

  • What industry is Neurizon Therapeutics in?

    Neurizon Therapeutics’s primary industry is Drug Discovery.

  • Is Neurizon Therapeutics a private or public company?

    Neurizon Therapeutics is a Public company.

  • What is Neurizon Therapeutics’s stock symbol?

    The ticker symbol for Neurizon Therapeutics is NUZ.

  • What is the current stock price of Neurizon Therapeutics?

    As of 19-Jun-2025 the stock price of Neurizon Therapeutics is $0.11.

  • What is the current market cap of Neurizon Therapeutics?

    The current market capitalization of Neurizon Therapeutics is $54.5M.

  • Who are Neurizon Therapeutics’s competitors?

    Novartis, Zynerba Pharmaceuticals, Inovio Pharmaceuticals, Genelux, and Dynavax Technologies are some of the 7 competitors of Neurizon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »